Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Efanesoctocog Alfa→

Efanesoctocog Alfa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2252477-42-0
Molecular formula
C13690H20958N3682O4376S136
Molecular weight
Not available
Drug class
Extended-half-life recombinant human coagulation factor VIII (Fc–VWF–XTEN fusion protein)
Mechanism of action
Replaces deficient factor VIII in haemophilia A. Activated factor VIII functions as a cofactor for activated factor IX in the tenase complex, accelerating factor X activation and thrombin generation.
Indications / reported uses
  • Treatment and prophylaxis of bleeding in congenital haemophilia A (factor VIII deficiency), across age groups under the cited EMA product information

Sources: EMA Altuvoct EPAR · EMA product information · US FDA Altuviio product page

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Efanesoctocog Alfa Environmental Risk Assessment (ERA) (the Efanesoctocog Alfa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.